You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《大行報告》大和升石藥(01093.HK)評級至「持有」 目標價維持9.9元
大和發表研究報告指,石藥集團(01093.HK)年初至今股價已反彈超過10%,明顯優於同業表現,認爲股價上漲主要是由於其估值相對較低,在流動性收緊及中國醫療保健行業增長存在不確定性的情況下,投資者將更傾向於投資防禦性股份。雖然石藥基本面並未出現強勁改善,但該行認爲下行風險有限,因此將石藥集團評級從「跑輸大市」上調至「持有」,維持目標價9.9元。 石藥日前宣佈斥資1.54億元人民幣收購廣州銘康生物51%權益,大和認爲,相對有吸引力的估值使石藥成爲中國醫療保健行業中的防禦性股份,雖然其產品管線較薄弱,但考慮到旗下產品「恩必普」的仿製藥未取得國家藥監局批準,預期該產品銷售將帶來持續增長,加上石藥近期已取得一系列創新藥物許可,成爲轉型爲創新藥企的起點。該行認爲,石藥仍需要提供更多產品管線相關的積極消息,纔可支持估值重估。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account